Opendata, web and dolomites

Need2immune SIGNED

Personalized liposomal cancer vaccines within days by rapid formulation screening

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Need2immune project word cloud

Explore the words cloud of the Need2immune project. It provides you a very rough idea of what is the project "Need2immune" about.

anticipated    oncology    modulators    therapeutic    play    patients    lower    agents    classes    injections    strategies    localised    onco    understand    losing    mechanism    attracting    action    period    clinical    painlessness    combination    reactions    ease    molecules    easily    administered    accelerate    injected    checkpoint    mobilise    microneedles    unprecedented    cancer    harbours    drastically    tumour    kill    nanoparticles    drug    possibility    immunotherapeutic    trackable    remissions    direct    adverse    last    shown    personalised    immunotherapies    host    toxicity    tools    complete    systemic    administration    risk    serum    immunotherapy    inject    eradication    cargo    locally    vaccine    sustained    administer    doses    intradermal    transdermal    microneedle    reagents    efficacy    immune    drugs    serious    levels    use    decrease    cells    drawbacks    bloodstream    mainstream    autoimmunity    causing    delivering    autoimmune    central    therapy   

Project "Need2immune" data sheet

The following table provides information about the project.

Coordinator
TECODEVELOPMENT GMBH 

Organization address
address: MARIE-CURIE-STR. 1
city: RHEINBACH
postcode: 53359
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 162˙806 €
 EC max contribution 162˙806 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2021-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TECODEVELOPMENT GMBH DE (RHEINBACH) coordinator 162˙806.00

Map

 Project objective

Cancer immunotherapy, defined as the ability to mobilise the host’s own immune system to kill cancer, has recently within the last 5 years, taken a central role within mainstream oncology. This period has seen the field rapidly accelerate towards unprecedented clinical responses in patients, and the development of novel classes of immunotherapeutic drugs. One approach has been to design more personalised immunotherapies along with new methods in delivering the therapeutic cargo. It is anticipated that this will play a defining role for cancer immunotherapy in terms of how to better achieve sustained remissions or complete eradication. One of the challenges in the future will be to understand how to administer these molecules since the current approach of systemic administration harbours the risk of causing serious toxicity and/or autoimmunity. This could drastically lower the serum levels of immune reagents needed with a decrease in adverse effects and lower risk of autoimmune reactions, without losing systemic efficacy. Currently, cancer immunotherapies are injected into the bloodstream but systemic injections have many drawbacks. It could be more effective therefore to inject this kind of therapy locally and directly to target tumour cells. This proposal will be to implement a more direct approach, where the immunotherapy's effects could be more easily controlled, with also the possibility for lower doses to be administered. Recently, microneedles have been attracting attention as new drug delivery tools. The microneedle has already been shown to be a highly effective intradermal and transdermal vaccine delivery method due to its mechanism of action, painlessness and ease of use. The goal is therefore to use microneedles to deliver localised doses of combination immunotherapies, e.g. vaccine with checkpoint modulators, in nanoparticles, as the focus of a novel approach to developing new strategies for the trackable delivery of onco-immunotherapeutic agents.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEED2IMMUNE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEED2IMMUNE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More  

SpaTime_AnTB (2020)

Single-cell spatiotemporal analysis of Mycobacterium tuberculosis responses to antibiotics within host microenvironments

Read More  

TCFLAND2SEA (2020)

Thawing Carbon From LAND to SEA: Microbial Degradation of Organic Matter and Response to Thawing Permafrost in the Northeast Siberian Land-Shelf System

Read More